Compare
Abbott Laboratories vs Boston Scientific
MonkScore ranges and fundamentals, side by side
Key facts
Abbott Laboratories and Boston Scientific: key facts
- In fiscal 2025, Abbott Laboratories reported revenue of $44.3B and net income of $6.5B.
- In fiscal 2025, Boston Scientific Corporation reported revenue of $20.1B and net income of $2.9B.
- Abbott Laboratories's revenue grew 0.7% a year from fiscal 2021 to fiscal 2025.
- Boston Scientific Corporation's revenue grew 14.0% a year from fiscal 2021 to fiscal 2025.
- Abbott Laboratories's free cash flow was positive in 5 of the 5 fiscal years from 2021 to 2025.
- Boston Scientific Corporation's free cash flow was positive in 5 of the 5 fiscal years from 2021 to 2025.
- In the twelve months to 30 September 2026, Abbott Laboratories reported revenue of $48.2B and net income of $4.7B.
- In the twelve months to 30 September 2026, Boston Scientific Corporation reported revenue of $21.1B and net income of $3.5B.
Side by side
Abbott Laboratories and Boston Scientific, side by side
Each figure is in the company's reporting currency, with its fiscal year or the date of its last report.
| Figure | Abbott LaboratoriesNYSE:ABT | Boston Scientific CorporationNYSE:BSX |
|---|---|---|
| MonkScore | ||
| MonkScore range | 30–40as of October 2026 | 40–50as of October 2026 |
| Sector rank | 464 of 628 in Healthcare | 372 of 628 in Healthcare |
| How this score is madeDisclaimer | ||
| Profile | ||
| Sector | Healthcare | Healthcare |
| Industry | Medical - Devices | Medical - Devices |
| Latest fiscal year | ||
| Revenue | $44.3BFY 2025 | $20.1BFY 2025 |
| Net income | $6.5BFY 2025 | $2.9BFY 2025 |
| Free cash flow | $7.4BFY 2025 | $3.7BFY 2025 |
| Operating cash flow | $9.6BFY 2025 | $4.5BFY 2025 |
| Total debt | $15.1BFY 2025 | $12.4BFY 2025 |
| Cash | $8.5BFY 2025 | $2.0BFY 2025 |
| Last 12 months | ||
| Revenue | $48.2Bto 30 September 2026 | $21.1Bto 30 September 2026 |
| Net income | $4.7Bto 30 September 2026 | $3.5Bto 30 September 2026 |
| Free cash flow | $8.7Bto 30 September 2026 | $3.6Bto 30 September 2026 |
| Operating cash flow | $9.9Bto 30 September 2026 | $4.5Bto 30 September 2026 |
| Total debt | $32.6Bto 30 September 2026 | $12.6Bto 30 September 2026 |
| Cash | $5.1Bto 30 September 2026 | $539.0Mto 30 September 2026 |
Company pages
Each company on its own
MonkStreet provides research, not investment advice.